Overview

Pharmacokinetics and Safety of Vilaprisan in Renal Impairment

Status:
Completed
Trial end date:
2019-02-06
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the pharmacokinetics of vilaprisan in subjects with moderate to severe renal impairment compared with matched subjects with normal renal function.
Phase:
Phase 1
Details
Lead Sponsor:
Bayer